ArticleCancer discovery2016
Successful Treatment of a Patient with Glioblastoma and a Germline POLE Mutation: Where Next?
Article in Cancer discovery, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Checkpoint: Inspecting the barriers in glioblastoma immunotherapies.Seminars in cancer biology · 2022Review
- Enhanced polymerase activity permits efficient synthesis by cancer-associated DNA polymerase ϵ variants at low dNTP levels.Nucleic acids research · 2022Article
- Pembrolizumab and Trastuzumab in High Tumor Mutational Burden and POLE-Mutated HER2-Positive Refractory Breast Cancer.The oncologist · 2022Article
- Review
- Tumor mutational burden and purity adjustment before and after treatment with temozolomide in 27 paired samples of glioblastoma: a prospective study.Molecular oncology · 2022Article
- Genomic profiling of newly diagnosed glioblastoma patients and its potential for clinical utility - a prospective, translational study.Molecular oncology · 2020Article
- Prostate carcinogenesis: inflammatory storms.Nature reviews. Cancer · 2020Review
- The efficacy of DNA mismatch repair enzyme immunohistochemistry as a screening test for hypermutated gliomas.Acta neuropathologica communications · 2020Article
- Replicative DNA polymerase defects in human cancers: Consequences, mechanisms, and implications for therapy.DNA repair · 2017Review
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
Abstract
Hypermutation and elevated neoantigen count in glioblastoma occurred in a patient harboring a germline POLE mutation and are associated with a clinical and antitumor immune response to PD-1 blockade. Cancer Discov; 6(11); 1210-11. ©2016 AACR.See related article by Johanns et al., p. 1230.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.